Symbols / VYGR $4.14 +0.49% Voyager Therapeutics, Inc.
VYGR Chart
About
Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. Its product pipeline includes VY1706, a tau silencing gene therapy and VY7523, an anti-tau antibody program for the treatment of alzheimer's disease. The company also provides research program for the treatment of Huntington's disease. In addition, it offers TRACER, an adeno-associated virus (AAV) capsid discovery platform; ALPL-VYGR-NeuroShuttle, to target an undisclosed neurological disease; and develops selective small molecules for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia with TDP-43 pathology. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Transition Bio, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
Fundamentals
Scroll to Statements| Market Cap | 246.74M | Enterprise Value | 86.79M | Income | -119.72M | Sales | 40.37M | Book/sh | 3.32 | Cash/sh | 3.30 |
| Dividend Yield | — | Payout | 0.00% | Employees | 141 | IPO | — | P/E | — | Forward P/E | -2.42 |
| PEG | — | P/S | 6.11 | P/B | 1.25 | P/C | — | EV/EBITDA | -0.70 | EV/Sales | 2.15 |
| Quick Ratio | 7.51 | Current Ratio | 7.64 | Debt/Eq | 18.61 | LT Debt/Eq | — | EPS (ttm) | -2.04 | EPS next Y | -1.71 |
| EPS Growth | — | Revenue Growth | 144.30% | Earnings | 2026-05-11 | ROA | -24.86% | ROE | -48.29% | ROIC | — |
| Gross Margin | -227.62% | Oper. Margin | -172.35% | Profit Margin | -296.53% | Shs Outstand | 59.60M | Shs Float | 47.30M | Short Float | 6.49% |
| Short Ratio | 3.56 | Short Interest | — | 52W High | 5.55 | 52W Low | 2.65 | Beta | 1.38 | Avg Volume | 700.44K |
| Volume | 424.46K | Target Price | $14.89 | Recom | Strong_buy | Prev Close | $4.12 | Price | $4.14 | Change | 0.49% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-03-17 | reit | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-11-12 | main | HC Wainwright & Co. | Buy → Buy | $25 |
| 2025-09-15 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-08-07 | main | Wedbush | Outperform → Outperform | $8 |
| 2025-04-08 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-03-13 | main | Canaccord Genuity | Buy → Buy | $12 |
| 2025-03-13 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-03-12 | main | Wells Fargo | Overweight → Overweight | $10 |
| 2025-03-12 | reit | Wedbush | Outperform → Outperform | — |
| 2025-03-12 | reit | Cantor Fitzgerald | Overweight → Overweight | — |
| 2025-03-03 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-01-27 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2025-01-10 | init | Cantor Fitzgerald | — → Overweight | $6 |
| 2024-12-02 | init | Citigroup | — → Buy | $12 |
| 2024-11-14 | main | Canaccord Genuity | Buy → Buy | $14 |
| 2024-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-10-24 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-10-16 | init | Leerink Partners | — → Outperform | $15 |
| 2024-08-20 | reit | HC Wainwright & Co. | Buy → Buy | $30 |
| 2024-08-07 | main | Wedbush | Neutral → Neutral | $7 |
- VYGR Stock Chart | VOYAGER THERAPEUTICS INC (NASDAQ:VYGR) - ChartMill Fri, 17 Apr 2026 07
- Voyager Therapeutics (VYGR) outlines CFO exit and new finance leaders - Stock Titan ue, 21 Apr 2026 20
- Voyager Therapeutics (VYGR) Stock: Overpriced in Market? (Trend Strengthens) 2026-04-20 - RSI Overbought Stocks - UBND thành phố Hải Phòng Mon, 20 Apr 2026 15
- Insider Sale: President and CEO of $VYGR Sells 11,511 Shares - Quiver Quantitative Fri, 03 Apr 2026 07
- Voyager Therapeutics: 'Strong Buy' On Inflection Points For VY7523 In AD For 2026 - Seeking Alpha Mon, 13 Apr 2026 07
- Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates - Yahoo Finance Mon, 09 Mar 2026 07
- Voyager Therapeutics Announces CFO Resignation and Finance Leadership Changes - TipRanks ue, 21 Apr 2026 20
- With Voyager Therapeutics Stock Sliding, Have You Assessed The Risk? - Trefis Sat, 20 Dec 2025 08
- $VYGR stock is up 19% today. Here's what we see in our data. - Quiver Quantitative ue, 10 Mar 2026 07
- Voyager Therapeutics (VYGR): Strong Q3 Prompts Bullish Coverage - Yahoo Finance Wed, 10 Dec 2025 08
- Voyager Therapeutics (VYGR) CEO sells shares for RSU tax withholding - Stock Titan Fri, 03 Apr 2026 07
- Does Voyager Therapeutics’ (VYGR) Widening Annual Loss Redefine the Risk-Reward in Its Neurology Pipeline? - Yahoo Finance hu, 12 Mar 2026 07
- VYGR SEC Filings - Voyager Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan hu, 02 Apr 2026 22
- Insider Sale: COO & CBO of $VYGR Sells 6,458 Shares - Quiver Quantitative hu, 26 Feb 2026 08
- Voyager Therapeutics (VYGR) awards 50,000 RSUs to legal chief - Stock Titan Fri, 03 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
40.37
-49.53%
|
80.00
-68.00%
|
250.01
+511.16%
|
40.91
|
| Operating Revenue |
|
40.37
-49.53%
|
80.00
-68.00%
|
250.01
+511.16%
|
40.91
|
| Operating Expense |
|
172.22
+5.47%
|
163.29
+27.57%
|
127.99
+39.51%
|
91.74
|
| Research And Development |
|
134.67
+5.74%
|
127.37
+38.19%
|
92.17
+51.69%
|
60.76
|
| Selling General And Administration |
|
37.54
+4.52%
|
35.92
+0.27%
|
35.82
+15.63%
|
30.98
|
| General And Administrative Expense |
|
37.54
+4.52%
|
35.92
+0.27%
|
35.82
+15.63%
|
30.98
|
| Other Gand A |
|
37.54
+4.52%
|
35.92
+0.27%
|
35.82
+15.63%
|
30.98
|
| Total Expenses |
|
172.22
+5.47%
|
163.29
+27.57%
|
127.99
+39.51%
|
91.74
|
| Operating Income |
|
-131.84
-58.30%
|
-83.29
-168.26%
|
122.01
+340.01%
|
-50.84
|
| Total Operating Income As Reported |
|
-131.84
-58.30%
|
-83.29
-168.26%
|
122.01
+340.01%
|
-50.84
|
| EBITDA |
|
-127.78
-62.67%
|
-78.56
-162.12%
|
126.45
+383.24%
|
-44.65
|
| Normalized EBITDA |
|
-127.78
-62.67%
|
-78.56
-162.12%
|
126.45
+383.24%
|
-44.65
|
| Reconciled Depreciation |
|
4.06
-14.18%
|
4.73
+6.53%
|
4.44
-28.27%
|
6.19
|
| EBIT |
|
-131.84
-58.30%
|
-83.29
-168.26%
|
122.01
+340.01%
|
-50.84
|
| Net Income |
|
-119.72
-84.18%
|
-65.00
-149.12%
|
132.33
+385.14%
|
-46.41
|
| Pretax Income |
|
-119.58
-85.86%
|
-64.34
-148.11%
|
133.74
+388.28%
|
-46.39
|
| Net Non Operating Interest Income Expense |
|
10.62
-42.07%
|
18.33
+56.37%
|
11.72
+554.07%
|
1.79
|
| Net Interest Income |
|
10.62
-42.07%
|
18.33
+56.37%
|
11.72
+554.07%
|
1.79
|
| Other Income Expense |
|
1.65
+165.11%
|
0.62
+20633.33%
|
0.00
-99.89%
|
2.65
|
| Other Non Operating Income Expenses |
|
1.65
+165.11%
|
0.62
+20633.33%
|
0.00
-99.89%
|
2.65
|
| Tax Provision |
|
0.14
-78.35%
|
0.67
-52.77%
|
1.41
+8700.00%
|
0.02
|
| Tax Rate For Calcs |
|
0.00
-100.00%
|
0.00
+2000.00%
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-119.72
-84.18%
|
-65.00
-149.12%
|
132.33
+385.14%
|
-46.41
|
| Net Income From Continuing Operation Net Minority Interest |
|
-119.72
-84.18%
|
-65.00
-149.12%
|
132.33
+385.14%
|
-46.41
|
| Net Income From Continuing And Discontinued Operation |
|
-119.72
-84.18%
|
-65.00
-149.12%
|
132.33
+385.14%
|
-46.41
|
| Net Income Continuous Operations |
|
-119.72
-84.18%
|
-65.00
-149.12%
|
132.33
+385.14%
|
-46.41
|
| Normalized Income |
|
-119.72
-84.18%
|
-65.00
-149.12%
|
132.33
+385.14%
|
-46.41
|
| Net Income Common Stockholders |
|
-119.72
-84.18%
|
-65.00
-149.12%
|
132.33
+385.14%
|
-46.41
|
| Diluted EPS |
|
—
|
-1.13
-138.05%
|
2.97
+345.45%
|
-1.21
|
| Basic EPS |
|
—
|
-1.13
-136.69%
|
3.08
+354.55%
|
-1.21
|
| Basic Average Shares |
|
—
|
57.67
+34.05%
|
43.02
+12.16%
|
38.36
|
| Diluted Average Shares |
|
—
|
57.67
+29.39%
|
44.57
+16.20%
|
38.36
|
| Diluted NI Availto Com Stockholders |
|
-119.72
-84.18%
|
-65.00
-149.12%
|
132.33
+385.14%
|
-46.41
|
| Total Other Finance Cost |
|
-10.62
+42.07%
|
-18.33
-56.37%
|
-11.72
-554.07%
|
-1.79
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Assets |
|
252.28
-35.81%
|
393.05
+11.89%
|
351.28
+120.44%
|
159.36
|
| Current Assets |
|
202.69
-26.78%
|
276.81
-13.41%
|
319.68
+156.78%
|
124.50
|
| Cash Cash Equivalents And Short Term Investments |
|
196.45
-26.34%
|
266.68
+15.51%
|
230.88
+94.26%
|
118.85
|
| Cash And Cash Equivalents |
|
65.30
-8.50%
|
71.37
+3.73%
|
68.80
-30.47%
|
98.96
|
| Cash Equivalents |
|
51.16
-14.24%
|
59.66
-9.04%
|
65.59
-28.49%
|
91.72
|
| Cash Financial |
|
14.14
+20.75%
|
11.71
+264.43%
|
3.21
-55.59%
|
7.24
|
| Other Short Term Investments |
|
131.15
-32.85%
|
195.32
+20.51%
|
162.07
+714.89%
|
19.89
|
| Receivables |
|
2.92
-35.09%
|
4.49
-94.68%
|
84.45
+13116.74%
|
0.64
|
| Accounts Receivable |
|
1.76
+17.09%
|
1.50
-98.12%
|
80.15
|
0.00
|
| Accrued Interest Receivable |
|
1.00
-56.60%
|
2.31
+139.73%
|
0.96
+152.36%
|
0.38
|
| Prepaid Assets |
|
1.05
-62.03%
|
2.76
+59.91%
|
1.73
+121.57%
|
0.78
|
| Hedging Assets Current |
|
—
|
—
|
—
|
—
|
| Other Current Assets |
|
2.28
-20.77%
|
2.87
+9.36%
|
2.63
-37.92%
|
4.23
|
| Total Non Current Assets |
|
49.59
-57.34%
|
116.24
+267.89%
|
31.60
-9.35%
|
34.86
|
| Net PPE |
|
41.61
-12.69%
|
47.66
+58.86%
|
30.00
-10.01%
|
33.34
|
| Gross PPE |
|
60.77
-4.49%
|
63.62
+41.25%
|
45.04
-10.89%
|
50.55
|
| Accumulated Depreciation |
|
-19.15
-20.01%
|
-15.96
-6.12%
|
-15.04
+12.61%
|
-17.21
|
| Properties |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Machinery Furniture Equipment |
|
2.44
+4.50%
|
2.33
-11.09%
|
2.62
+12.52%
|
2.33
|
| Construction In Progress |
|
—
|
—
|
—
|
—
|
| Other Properties |
|
51.48
-6.07%
|
54.80
+55.19%
|
35.31
-0.98%
|
35.66
|
| Leases |
|
6.85
+5.60%
|
6.49
-8.71%
|
7.11
-43.40%
|
12.55
|
| Investments And Advances |
|
5.24
-92.02%
|
65.70
|
0.00
|
—
|
| Non Current Prepaid Assets |
|
—
|
—
|
—
|
—
|
| Other Non Current Assets |
|
2.74
-4.80%
|
2.87
+80.41%
|
1.59
+5.15%
|
1.51
|
| Total Liabilities Net Minority Interest |
|
56.20
-39.76%
|
93.29
-18.85%
|
114.96
+14.58%
|
100.34
|
| Current Liabilities |
|
26.54
-46.69%
|
49.79
-22.82%
|
64.51
-11.13%
|
72.59
|
| Payables And Accrued Expenses |
|
8.02
-29.74%
|
11.41
-3.37%
|
11.81
+102.87%
|
5.82
|
| Payables |
|
5.01
+25.45%
|
4.00
+149.13%
|
1.60
-37.49%
|
2.57
|
| Accounts Payable |
|
5.01
+25.45%
|
4.00
+149.13%
|
1.60
-37.49%
|
2.57
|
| Current Accrued Expenses |
|
3.01
-59.47%
|
7.42
-27.33%
|
10.21
+213.45%
|
3.26
|
| Pensionand Other Post Retirement Benefit Plans Current |
|
9.09
+34.64%
|
6.75
+2.09%
|
6.61
+45.08%
|
4.56
|
| Current Debt And Capital Lease Obligation |
|
7.84
+8.48%
|
7.23
+125.84%
|
3.20
+12.99%
|
2.83
|
| Current Capital Lease Obligation |
|
7.84
+8.48%
|
7.23
+125.84%
|
3.20
+12.99%
|
2.83
|
| Current Deferred Liabilities |
|
1.59
-93.48%
|
24.39
-43.11%
|
42.88
-27.78%
|
59.38
|
| Current Deferred Revenue |
|
1.59
-93.48%
|
24.39
-43.11%
|
42.88
-27.78%
|
59.38
|
| Total Non Current Liabilities Net Minority Interest |
|
29.66
-31.82%
|
43.50
-13.78%
|
50.45
+81.85%
|
27.75
|
| Long Term Debt And Capital Lease Obligation |
|
28.66
-21.48%
|
36.50
+113.52%
|
17.09
-15.77%
|
20.29
|
| Long Term Capital Lease Obligation |
|
28.66
-21.48%
|
36.50
+113.52%
|
17.09
-15.77%
|
20.29
|
| Non Current Deferred Liabilities |
|
0.00
-100.00%
|
6.00
-81.45%
|
32.36
+401.69%
|
6.45
|
| Non Current Deferred Revenue |
|
0.00
-100.00%
|
6.00
-81.45%
|
32.36
+401.69%
|
6.45
|
| Other Non Current Liabilities |
|
1.00
+0.00%
|
1.00
+0.00%
|
1.00
-0.10%
|
1.00
|
| Stockholders Equity |
|
196.08
-34.59%
|
299.76
+26.84%
|
236.32
+300.41%
|
59.02
|
| Common Stock Equity |
|
196.08
-34.59%
|
299.76
+26.84%
|
236.32
+300.41%
|
59.02
|
| Capital Stock |
|
0.06
+7.27%
|
0.06
+25.00%
|
0.04
+15.79%
|
0.04
|
| Common Stock |
|
0.06
+7.27%
|
0.06
+25.00%
|
0.04
+15.79%
|
0.04
|
| Preferred Stock |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Share Issued |
|
59.05
+7.89%
|
54.73
+24.28%
|
44.04
+14.05%
|
38.61
|
| Ordinary Shares Number |
|
59.05
+7.89%
|
54.73
+24.28%
|
44.04
+14.05%
|
38.61
|
| Additional Paid In Capital |
|
641.89
+2.49%
|
626.30
+25.89%
|
497.51
+9.89%
|
452.71
|
| Retained Earnings |
|
-445.90
-36.70%
|
-326.18
-24.89%
|
-261.18
+33.63%
|
-393.51
|
| Gains Losses Not Affecting Retained Earnings |
|
0.03
+107.86%
|
-0.41
-747.92%
|
-0.05
+78.08%
|
-0.22
|
| Other Equity Adjustments |
|
0.03
+107.86%
|
-0.41
-747.92%
|
-0.05
+78.08%
|
-0.22
|
| Total Equity Gross Minority Interest |
|
196.08
-34.59%
|
299.76
+26.84%
|
236.32
+300.41%
|
59.02
|
| Total Capitalization |
|
196.08
-34.59%
|
299.76
+26.84%
|
236.32
+300.41%
|
59.02
|
| Working Capital |
|
176.15
-22.41%
|
227.02
-11.03%
|
255.18
+391.59%
|
51.91
|
| Invested Capital |
|
196.08
-34.59%
|
299.76
+26.84%
|
236.32
+300.41%
|
59.02
|
| Total Debt |
|
36.50
-16.53%
|
43.73
+115.46%
|
20.29
-12.25%
|
23.13
|
| Capital Lease Obligations |
|
36.50
-16.53%
|
43.73
+115.46%
|
20.29
-12.25%
|
23.13
|
| Net Tangible Assets |
|
196.08
-34.59%
|
299.76
+26.84%
|
236.32
+300.41%
|
59.02
|
| Tangible Book Value |
|
196.08
-34.59%
|
299.76
+26.84%
|
236.32
+300.41%
|
59.02
|
| Available For Sale Securities |
|
5.24
-92.02%
|
65.70
|
—
|
—
|
| Duefrom Related Parties Current |
|
0.15
-77.66%
|
0.68
-79.77%
|
3.34
+1200.00%
|
0.26
|
| Investmentin Financial Assets |
|
5.24
-92.02%
|
65.70
|
0.00
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-132.47
-765.23%
|
-15.31
-119.65%
|
77.92
+722.90%
|
-12.51
|
| Cash Flow From Continuing Operating Activities |
|
-132.47
-765.23%
|
-15.31
-119.65%
|
77.92
+722.90%
|
-12.51
|
| Net Income From Continuing Operations |
|
-119.72
-84.18%
|
-65.00
-149.12%
|
132.33
+385.14%
|
-46.41
|
| Depreciation Amortization Depletion |
|
4.06
-14.18%
|
4.73
+6.53%
|
4.44
-28.27%
|
6.19
|
| Depreciation |
|
4.06
-14.18%
|
4.73
+6.53%
|
4.44
-28.27%
|
6.19
|
| Depreciation And Amortization |
|
4.06
-14.18%
|
4.73
+6.53%
|
4.44
-28.27%
|
6.19
|
| Other Non Cash Items |
|
—
|
—
|
—
|
-2.47
|
| Stock Based Compensation |
|
14.79
+0.01%
|
14.79
+32.57%
|
11.15
+19.36%
|
9.34
|
| Asset Impairment Charge |
|
0.00
-100.00%
|
2.78
|
0.00
|
0.00
|
| Operating Gains Losses |
|
0.14
-72.35%
|
0.51
+186.52%
|
0.18
-52.79%
|
0.38
|
| Gain Loss On Sale Of PPE |
|
0.14
-72.35%
|
0.51
+186.52%
|
0.18
-52.79%
|
0.38
|
| Change In Working Capital |
|
-28.76
-182.51%
|
34.86
+152.37%
|
-66.56
-425.13%
|
20.47
|
| Change In Receivables |
|
0.27
-99.67%
|
81.31
+197.69%
|
-83.23
-17622.95%
|
0.47
|
| Changes In Account Receivables |
|
-0.26
-100.33%
|
78.65
+198.12%
|
-80.15
|
0.00
|
| Change In Prepaid Assets |
|
3.62
+237.69%
|
-2.63
-3556.58%
|
0.08
+103.86%
|
-1.97
|
| Change In Payables And Accrued Expense |
|
-1.48
-470.38%
|
-0.26
-103.23%
|
8.04
+795.93%
|
-1.16
|
| Change In Accrued Expense |
|
-2.50
+5.73%
|
-2.65
-129.44%
|
9.01
+386.12%
|
-3.15
|
| Change In Payable |
|
1.02
-57.48%
|
2.39
+348.65%
|
-0.96
-148.29%
|
1.99
|
| Change In Account Payable |
|
1.02
-57.48%
|
2.39
+348.65%
|
-0.96
-148.29%
|
1.99
|
| Change In Other Working Capital |
|
-28.81
+35.76%
|
-44.84
-576.33%
|
9.41
-60.33%
|
23.73
|
| Change In Other Current Assets |
|
4.87
+5.96%
|
4.60
+132.76%
|
1.98
-40.33%
|
3.31
|
| Change In Other Current Liabilities |
|
-7.23
-117.68%
|
-3.32
-17.19%
|
-2.83
+27.77%
|
-3.92
|
| Investing Cash Flow |
|
125.45
+232.24%
|
-94.86
+33.03%
|
-141.64
-1830.00%
|
-7.34
|
| Cash Flow From Continuing Investing Activities |
|
125.45
+232.24%
|
-94.86
+33.03%
|
-141.64
-1830.00%
|
-7.34
|
| Net PPE Purchase And Sale |
|
-2.60
+26.27%
|
-3.52
-8.14%
|
-3.26
-30.71%
|
-2.49
|
| Purchase Of PPE |
|
-2.60
+26.27%
|
-3.52
-8.14%
|
-3.26
-30.71%
|
-2.49
|
| Sale Of PPE |
|
—
|
—
|
—
|
—
|
| Capital Expenditure |
|
-2.60
+26.27%
|
-3.52
-8.14%
|
-3.26
-30.71%
|
-2.49
|
| Net Investment Purchase And Sale |
|
128.04
+240.18%
|
-91.34
+34.00%
|
-138.39
-2754.52%
|
-4.85
|
| Purchase Of Investment |
|
-133.93
+71.24%
|
-465.69
-107.92%
|
-223.97
-308.34%
|
-54.85
|
| Sale Of Investment |
|
261.97
-30.02%
|
374.35
+337.42%
|
85.58
+71.16%
|
50.00
|
| Financing Cash Flow |
|
0.82
-99.28%
|
114.02
+238.88%
|
33.65
+2931.08%
|
1.11
|
| Cash Flow From Continuing Financing Activities |
|
0.82
-99.28%
|
114.02
+238.88%
|
33.65
+2931.08%
|
1.11
|
| Net Common Stock Issuance |
|
0.00
-100.00%
|
112.78
+262.39%
|
31.12
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.82
-34.03%
|
1.24
-50.99%
|
2.52
+127.39%
|
1.11
|
| Changes In Cash |
|
-6.21
-261.34%
|
3.85
+112.79%
|
-30.08
-60.52%
|
-18.74
|
| Beginning Cash Position |
|
74.24
+5.46%
|
70.39
-29.94%
|
100.47
-15.72%
|
119.21
|
| End Cash Position |
|
68.04
-8.36%
|
74.24
+5.46%
|
70.39
-29.94%
|
100.47
|
| Free Cash Flow |
|
-135.06
-617.24%
|
-18.83
-125.22%
|
74.66
+597.75%
|
-15.00
|
| Amortization Of Securities |
|
-2.97
+62.69%
|
-7.97
-119.77%
|
-3.63
-22562.50%
|
-0.02
|
| Common Stock Issuance |
|
0.00
-100.00%
|
112.78
+262.39%
|
31.12
|
0.00
|
| Issuance Of Capital Stock |
|
0.00
-100.00%
|
112.78
+262.39%
|
31.12
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-21 View
- 42026-04-03 View
- 42026-04-03 View
- 8-K2026-03-09 View
- 10-K2026-03-09 View
- 42026-02-26 View
- 42026-02-26 View
- 42026-02-26 View
- 42026-02-26 View
- 42026-02-20 View
- 42026-02-20 View
- 42026-02-20 View
- 8-K2026-02-12 View
- 42026-02-11 View
- 42026-02-11 View
- 42026-02-11 View
- 42026-02-10 View
- 42026-02-10 View
- 42026-02-10 View
- 42026-02-10 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|